The key to unlocking early cancer detection.

Beken Bio develops minimally invasive liquid biopsies that will help diagnose cancer at its earliest stage using our patent-pending 3D REVEAL™ engine to open the door for effective treatment when time is most crucial.

The Future of Prevention.

Using our body's most abundant messengers to intercept cancer

2 in 5 people will be diagnosed with cancer at some point in their life, and by 2040, global cancer deaths are projected to exceed 16.2 million a year.

We envision a world where this estimation isn’t reality, and the question of late-stage diagnosis is answered with a solution.

Beken Bio’s 3D REVEAL™ Engine identifies novel cancer biomarkers that show up in the blood before symptoms are present, empowering doctors with the earliest form of detection possible, and potentially reducing cancer related deaths through clinically qualified diagnostic tests.

39.5%

of people will be diagnosed with cancer at some point in their lives.

Those who discover it at
an early stage are

90%

more likely to survive.

38% of people will be diagnosed with cancer at some point in their lives.

Those who discover it at an early stage are 90% more likely to survive.

Key To The Engine.

Key to the Engine.

3D REVEAL™ Does The Trick

Beken Bio is pioneering its proprietary 3D Recapitulation of Extracellular Vesicles bearing Enriched Antigens for Liquid biopsy, also known as our 3D REVEAL™ engine.

By tricking cancer cells into producing EVs as if they are still in the tumor, we’re able to pinpoint the exact molecular signature exclusive to EVs of a given cancer type, unlocking the cell signaling code to early detection.